Metrics to compare | MDWD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMDWDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.5x | −0.9x | −0.4x | |
PEG Ratio | 1.06 | −0.15 | 0.00 | |
Price/Book | 4.7x | 1.2x | 2.6x | |
Price / LTM Sales | 13.5x | 2.0x | 3.0x | |
Upside (Analyst Target) | 104.5% | 27.1% | 50.7% | |
Fair Value Upside | Unlock | 16.5% | 6.5% | Unlock |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.